Nuvectis Pharma (NVCT) Prices 1.92M Share Offering at $8.25/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
July 27, 2022 8:00 AM EDTFort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (Nuvectis or the Company), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, announced today that it has entered into definitive agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1,924,689 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $8.25 per share and preferred investment option. The investors also purchased preferred investment options to purchase up to an aggregate of 1,924,689 shares of common... More
